-
公开(公告)号：WO2006119146A1
公开(公告)日：2006-11-09
申请号：PCT/US2006/016526
申请日：2006-05-01
Applicant: ARRAY BIOPHARMA INC. , HANS, Jeremy , WALLACE, Eli M. , ZHAO, Qian , ALLEN, Shelley , LAIRD, Ellen , LYSSIKATOS, Joseph P. , ROBINSON, John E. , CORRETTE, Christopher P. , DELISLE, Robert Kirk
Inventor： HANS, Jeremy , WALLACE, Eli M. , ZHAO, Qian , ALLEN, Shelley , LAIRD, Ellen , LYSSIKATOS, Joseph P. , ROBINSON, John E. , CORRETTE, Christopher P. , DELISLE, Robert Kirk
IPC: C07D417/04
CPC classification number: C07D513/04 , C07D285/12 , C07D417/04 , C07D417/14 , C07D419/04 , C07D471/04 , C07D487/04 , C07D495/04 , C07D497/04 , C07F9/65395
Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
Abstract translation: 本发明涉及有丝分裂驱动蛋白，特别是KSP的抑制剂，以及生产这些抑制剂的方法。 本发明还提供了包含本发明抑制剂的药物组合物以及使用该抑制剂和药物组合物治疗和预防各种疾病的方法。
-
公开(公告)号：WO2013055645A1
公开(公告)日：2013-04-18
申请号：PCT/US2012/059282
申请日：2012-10-09
Applicant: ARRAY BIOPHARMA INC. , BOYS, Mark Laurence , BURGESS, Laurence E. , EARY, C. Todd , GRONEBERG, Robert , HACHE, Bruno P. , HARVEY, Darren , HICKEN, Erik James , KRASER, Christopher F. , LAIRD, Ellen , MORENO, David A. , MUNSON, Mark C. , REN, Li , ROBINSON, John E. , SCHLACHTER, Stephen T.
Inventor： BOYS, Mark Laurence , BURGESS, Laurence E. , EARY, C. Todd , GRONEBERG, Robert , HACHE, Bruno P. , HARVEY, Darren , HICKEN, Erik James , KRASER, Christopher F. , LAIRD, Ellen , MORENO, David A. , MUNSON, Mark C. , REN, Li , ROBINSON, John E. , SCHLACHTER, Stephen T.
IPC: C07D487/04 , A61K31/519 , A61P29/00 , A61P37/00
CPC classification number: C07D487/04
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X 1 and X 2 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
Abstract translation: R 1，R 2，R 3，R 4，R 5，R 6，X 1和X 2具有本说明书中给出的含义的式I化合物及其立体异构体及其药学上可接受的盐和溶剂合物是一种或多种JAK激酶的抑制剂，并且是有用的 治疗自身免疫性疾病，炎症性疾病，移植器官，组织和细胞排斥，以及血液系统疾病和恶性肿瘤及其并发症。
-
公开(公告)号：WO2010022081A1
公开(公告)日：2010-02-25
申请号：PCT/US2009/054198
申请日：2009-08-18
Applicant: ARRAY BIOPHARMA INC. , ALLEN, Shelley , DELISLE, Robert Kirk , GRESCHUK, Julie Marie , HICKEN, Erik James , LYSSIKATOS, Joseph P. , MARMSATER, Fredrik P. , MUNSON, Mark C. , ROBINSON, John E. , ZHAO, Qian
Inventor： ALLEN, Shelley , DELISLE, Robert Kirk , GRESCHUK, Julie Marie , HICKEN, Erik James , LYSSIKATOS, Joseph P. , MARMSATER, Fredrik P. , MUNSON, Mark C. , ROBINSON, John E. , ZHAO, Qian
IPC: C07D471/04 , A61K31/437 , A61P35/00
CPC classification number: C07D471/04
Abstract: Compounds of Formula (I): I in which B, R 1 , R 1a , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 and R 11 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.
Abstract translation: 式（I）的化合物：其中B，R1，R1a，R2，R3，R4，R5，R6，R7，R10和R11具有本说明书中给出的含义的I是可用于治疗疾病介导的受体酪氨酸抑制剂 通过PIM-1和/或PIM-2和/或PIM-3激酶。
-
公开(公告)号：WO2019113190A1
公开(公告)日：2019-06-13
申请号：PCT/US2018/064039
申请日：2018-12-05
Applicant: ARRAY BIOPHARMA INC.
Inventor： ALLEN, Shelley , BOYS, Mark Laurence , COOK, Adam , GAUDINO, John , HINKLIN, Ronald Jay , LAIRD, Ellen , MCNULTY, Oren T. , METCALF, Andrew T. , NEWHOUSE, Brad , ROBINSON, John E.
IPC: C07D471/04 , A61P35/00 , A61K31/437
Abstract: Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein Ring A, X 1 , X 2 , X 3 , R 1 , R 2 and R 3 are as defined herein, which are inhibitors of one or more TAM kinases and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor.
-
5.发明申请4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS 审中-公开4,6-取代的吡唑并[1,5-a]吡啶作为JANUS KINASE INHIBITORS
公开(公告)号：WO2016090285A1
公开(公告)日：2016-06-09
申请号：PCT/US2015/064062
申请日：2015-12-04
Applicant: ARRAY BIOPHARMA INC. , CELGENE CORPORATION
Inventor： ALLEN, Shelley , BOYS, Mark Laurence , CHICARELLI, Mark J. , FELL, Jay Bradford , FISCHER, John P. , GAUDINO, John , HICKEN, Erik James , HINKLIN, Ronald Jay , KRASER, Christopher F. , LAIRD, Ellen , ROBINSON, John E. , TANG, Tony P. , BURGESS, Laurence E. , RIEGER, Robert Andrew , PHENEGER, Jed , SATOH, Yoshitaka , LEFTHERIS, Katerina , RAHEJA, Raj K. , BENNETT, Brydon L.
IPC: C07D487/04 , A61K31/4985 , A61P29/00 , A61P37/00
CPC classification number: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K45/06
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R 1 , R 2 , R 3 and R 4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
Abstract translation: 式I化合物及其立体异构体及其药学上可接受的盐和溶剂化物，其中R1，R2，R3和R4具有说明书中给出的含义，是一种或多种JAK激酶的抑制剂，并且可用于治疗JAK激酶相关 疾病和病症，例如自身免疫性疾病，炎症性疾病，移植器官，组织和细胞的排斥，以及血液系统疾病和恶性肿瘤及其并发症。
-
Patent Agency Ranking6.发明公开4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS 审中-公开作为JANUS激酶抑制剂的4,6-取代 - 吡唑并[1,5-a]吡嗪
公开(公告)号：EP3227297A1
公开(公告)日：2017-10-11
申请号：EP15819933.1
申请日：2015-12-04
Applicant: Array Biopharma, Inc. , Celgene Corporation
Inventor： ALLEN, Shelley , BOYS, Mark Laurence , CHICARELLI, Mark J. , FELL, Jay Bradford , FISCHER, John P. , GAUDINO, John , HICKEN, Erik James , HINKLIN, Ronald Jay , KRASER, Christopher F. , LAIRD, Ellen , ROBINSON, John E. , TANG, Tony P. , BURGESS, Laurence E. , RIEGER, Robert Andrew , PHENEGER, Jed , SATOH, Yoshitaka , LEFTHERIS, Katerina , RAHEJA, Raj K. , BENNETT, Brydon L.
IPC: C07D487/04 , A61K31/4985 , A61P29/00 , A61P37/00
CPC classification number: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K45/06
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
Abstract translation: 式I化合物及其立体异构体及其药学上可接受的盐和溶剂化物，其中R 1，R 2，R 3和R 4具有说明书中给出的含义，为一种或多种JAK激酶的抑制剂，并且可用于治疗 JAK激酶相关的疾病和病症，如自身免疫性疾病，炎性疾病，移植器官，组织和细胞的排斥，以及血液病和恶性肿瘤及其并发症。
-
7.发明公开
公开(公告)号：EP3878451A1
公开(公告)日：2021-09-15
申请号：EP21152373.3
申请日：2015-12-04
Applicant: Array Biopharma Inc. , Celgene Corporation
Inventor： ALLEN, Shelley , BOYS, Mark Laurence , CHICARELLI, Mark J. , FELL, Jay Bradford , FISCHER, John P. , GAUDINO, John , HICKEN, Erik James , HINKLIN, Ronald Jay , KRASER, Christopher F. , LAIRD, Ellen , ROBINSON, John E. , TANG, Tony P. , BURGESS, Laurence E. , RIEGER, Robert Andrew , PHENEGER, Jed , SATOH, Yoshitaka , LEFTHERIS, Katerina , RAHEJA, Raj K. , BENNETT, Brydon L.
IPC: A61K31/4985 , C07D487/04 , A61P29/00 , A61P37/00
Abstract: Compounds of Formula I:
and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R 1 , R 2 , R 3 and R 4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.-
公开(公告)号：EP1879886B1
公开(公告)日：2014-07-09
申请号：EP06758821.0
申请日：2006-05-01
Applicant: Array Biopharma, Inc.
Inventor： HANS, Jeremy , WALLACE, Eli M. , ZHAO, Qian , ALLEN, Shelley , LAIRD, Ellen , LYSSIKATOS, Joseph P. , ROBINSON, John E. , CORRETTE, Christopher P. , DELISLE, Robert Kirk , VOEGTLI, Walter Charles
IPC: C07D417/04 , C07D417/14 , C07D419/04 , C07D471/04 , C07D487/04 , C07D495/04 , C07D513/04
CPC classification number: C07D513/04 , C07D285/12 , C07D417/04 , C07D417/14 , C07D419/04 , C07D471/04 , C07D487/04 , C07D495/04 , C07D497/04 , C07F9/65395
-
公开(公告)号：EP2766368A1
公开(公告)日：2014-08-20
申请号：EP12775905.8
申请日：2012-10-09
Applicant: Array Biopharma Inc.
Inventor： BOYS, Mark Laurence , BURGESS, Laurence E. , EARY, C. Todd , GRONEBERG, Robert , HACHE, Bruno P. , HARVEY, Darren , HICKEN, Erik James , KRASER, Christopher F. , LAIRD, Ellen , MORENO, David A. , MUNSON, Mark C. , REN, Li , ROBINSON, John E. , SCHLACHTER, Stephen T.
IPC: C07D487/04 , A61K31/519 , A61P29/00 , A61P37/00
CPC classification number: C07D487/04
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R
1 , R
2 , R
3 , R
4 , R
5 , R
6 , X
1 and X
2 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.Abstract translation: 其中R 1，R 2，R 3，R 4，R 5，R 6，X 1和X 2具有说明书中给出的含义的式I化合物及其立体异构体和药学上可接受的盐和溶剂合物是 一种或多种JAK激酶，并且可用于治疗自身免疫性疾病，炎性疾病，移植器官，组织和细胞的排斥，以及血液病和恶性肿瘤及其并发症。
-
公开(公告)号：EP1879886A1
公开(公告)日：2008-01-23
申请号：EP06758821.0
申请日：2006-05-01
Applicant: Array Biopharma, Inc.
Inventor： HANS, Jeremy , WALLACE, Eli M. , ZHAO, Qian , ALLEN, Shelley , LAIRD, Ellen , LYSSIKATOS, Joseph P. , ROBINSON, John E. , CORRETTE, Christopher P. , DELISLE, Robert Kirk , VOEGTLI, Walter Charles
IPC: C07D417/04
CPC classification number: C07D513/04 , C07D285/12 , C07D417/04 , C07D417/14 , C07D419/04 , C07D471/04 , C07D487/04 , C07D495/04 , C07D497/04 , C07F9/65395
Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.03 seconds)
